Skip to main content
TipRanks
Go Ultimate75% OFF

Cooper Co (COO) Revenue by Segment

671 Followers

Revenue by Segment

Shows how different parts of the business contribute to overall sales, highlighting strengths and potential areas for growth within the company's diverse operations.

$0.00$250.00M$500.00M$750.00M$1.00BJan 21Apr 21Jul 21Oct 21Jan 22Apr 22Jul 22Oct 22Jan 23Apr 23Jul 23Oct 23Jan 24Apr 24Jul 24Oct 24Jan 25Apr 25Jul 25Oct 25Jan 26Apr 26Jul 26
Chart Insights

CooperVision is the steady-growth engine—consistent organic lens demand and new product momentum (MiSight, daily silicone hydrogel) underpin resilience even as Asia softness and near-term margin pressure from FX, tariffs and inventory optimization bite. CooperSurgical is the faster-growth lever—fertility, genomics and capital equipment have materially lifted contribution since 2022, and management’s strategic review (broad external interest) could unlock value or introduce execution risk. Monitor how litigation payouts and any transaction proceeds affect buybacks, FCF allocation and near-term margin recovery.

COO Revenue by Segment

DateCooperVisionCooperSurgical
Jul 31, 2026$717.00M$349.20M
Apr 30, 2026$723.50M$358.00M
Jan 31, 2026$695.10M$329.00M
Oct 31, 2025$709.60M$355.60M
Jul 31, 2025$718.40M$341.90M
Apr 30, 2025$669.60M$332.70M
Jan 31, 2025$646.10M$318.60M
Oct 31, 2024$676.40M$342.00M
Jul 31, 2024$675.60M$327.20M
Apr 30, 2024$635.90M$306.70M
Jan 31, 2024$621.50M$310.10M
Oct 31, 2023$622.90M$304.20M
Jul 31, 2023$630.20M$300.00M
Apr 30, 2023$589.30M$288.10M
Jan 31, 2023$581.30M$277.20M
Oct 31, 2022$561.70M$286.30M
Jul 31, 2022$566.30M$277.10M
Apr 30, 2022$553.80M$276.00M
Jan 31, 2022$561.50M$225.70M
Oct 31, 2021$564.90M$194.20M
Jul 31, 2021$557.50M$205.90M
Apr 30, 2021$522.60M$196.90M
Jan 31, 2021$507.00M$173.50M
Oct 31, 2020$506.30M$175.30M
Jul 31, 2020$449.30M$128.90M
Apr 30, 2020$402.20M$122.70M
Jan 31, 2020$485.20M$161.00M